ArticleAntimicrobial agents and chemotherapy2003
Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Antiviral Chemotherapy in Avian Medicine-A Review.Viruses · 2024Review
- Activity of nucleic acid polymers in rodent models of HBV infection.Antiviral research · 2018Article
- Identification of anti-HBV activities inChinese medicine · 2017Article
- Mouse models for therapeutic vaccination against hepatitis B virus.Medical microbiology and immunology · 2015Review
- Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.PloS one · 2015Article
- Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.Antimicrobial agents and chemotherapy · 2013Article
- The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B.Journal of clinical and translational hepatology · 2013Review
- Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.Journal of virology · 2008Article
- DNA vaccine: a promising new approach for chronic hepatitis B therapy.Future virology · 2007Article
- Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism.World journal of gastroenterology · 2007Review
- Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.Clinical and vaccine immunology : CVI · 2006Article
- Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.Journal of virology · 2005Article
- Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Journal of virology · 2005Article
- Establishment and assessment of two methods for quantitative detection of serum duck hepatitis B virus DNA.World journal of gastroenterology · 2004Article
- Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Hepatocyte turnover during resolution of a transient hepadnaviral infection.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to test the efficacy of antiviral treatment with entecavir (ETV) in combination with DNA vaccines expressing duck hepatitis B virus (DHBV) antigens as a therapy for persistent DHBV infection in ducks. Ducks were inoculated with 10(9) DHBV genomes at 7 days of age, leading to widespread infection of the liver and viremia within 7 days, and were then treated orally with either ETV (0.1 mg/kg of body weight/day) or distilled water from 21 days posthatch for 244 days. Treatment with ETV caused a 4-log drop in serum DHBV DNA levels within 80 days and a slower 2- to 3-log drop in serum DHBV surface antigen (DHBsAg) levels within 120 days. Following withdrawal of ETV, levels of serum DHBV DNA and DHBsAg rebounded to match those in the water-treated animals within 40 days. Sequential liver biopsy samples collected throughout the study showed that ETV treatment reduced DHBV DNA replicative intermediates 70-fold in the liver, while the level of the stable, template form, covalently closed circular DNA decreased only 4-fold. ETV treatment reduced both the intensity of antigen staining and the percentage of antigen-positive hepatocytes in the liver, but the intensity of antigen staining in bile duct cells appeared not to be effected. Intramuscular administration of five doses of a DNA vaccine expressing the DHBV presurface, surface, precore, and core antigens, both alone and concurrently with ETV treatment, on days 50, 64, 78, 127, and 141 did not result in any significant effect on viral markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.